While some of these characteristics applied to patients across all dossiers (e.g. diagnosis of lung cancer and NSCLC), others only applied to very specific patient populations in individual dossiers (e.g. patients with a BRAF-V600 mutation [29, 30]). This evidence concerns the gene BRAF and non-small cell lung carcinoma.